TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Sinopharm Group Co ( (HK:1099) ).
Sinopharm Group Co. Ltd. announced the preliminary financial data for its subsidiary, Sinopharm Accord, for the nine months ending September 30, 2025. The report indicates a slight decrease in total revenue and net profit compared to the previous year, with total revenue down by 2.38% and net profit attributable to shareholders decreasing by 10.18%. Despite the decline in profits, the company saw an increase in total assets by 6.31% and equity attributable to shareholders by 4.30%, suggesting a stable financial position. These results may impact the company’s market positioning and stakeholder confidence, as they reflect both challenges and resilience in the current economic climate.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a leading company in the pharmaceutical industry, primarily engaged in the distribution and retail of pharmaceutical and healthcare products. The company operates in China and has a significant presence in the Hong Kong market.
Average Trading Volume: 5,562,333
Technical Sentiment Signal: Sell
Current Market Cap: HK$58.35B
For an in-depth examination of 1099 stock, go to TipRanks’ Overview page.